New leukemia drug shows promise against Gleevec resistance.
Ashraf
Haroon
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001555:Benzene Derivatives / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D001555:Benzene Derivatives; C499758:ON012380; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate